IMPORTANCE OF ANTIBODY ISOTYPE IN VAGINAL HIV TRANSMISSION
抗体同种型在艾滋病毒阴道传播中的重要性
基本信息
- 批准号:8358084
- 负责人:
- 金额:$ 5.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-05-01 至 2012-04-30
- 项目状态:已结题
- 来源:
- 关键词:Administrative SupplementAntibodiesFundingGrantHIVHIV InfectionsImmunoglobulin AImmunoglobulin GIntestinesJ-Chain ImmunoglobulinsMembraneMolecular ConformationMucous MembraneNational Center for Research ResourcesPaperPathogenesisPreparationPrimatesPrincipal InvestigatorRectumResearchResearch InfrastructureResourcesSourceUnited States National Institutes of HealthVaginacostintravenous administrationneutralizing antibodypreventresearch studysimian human immunodeficiency virustransmission processvaginal transmission
项目摘要
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
It is now clear that intestine and other mucosal tissues are of major importance in both the transmission as well as the early pathogenesis of HIV infection. We are currently determining whether antibodies of different isotypes are better for protecting the vaginal vault, and performed experiments to determine if there was preferential secretion. Last year we showed that HIV-specific IgA and IgG are preferentially secreted from the intestine (rectum) and vagina, respectively following intravenous administration of HIV-specific antibodies. Originally this was performed using antibodies against the membrane proximal external region (MPER) of HIV (2F5) but after receiving an administrative supplement to Dennis Burton at Scripps this year, we have also pursued this with other non-neutralizing antibodies (b12). However, we have not been able to demonstrate different levels of protection from vaginal transmission when any antibody to date in the IgA isotypes were used, and in fact IgG levels do seem to correlate better with protection. Whether this is a factor of not having the appropriate conformation (J-chain etc) of the IgA version of the same antibody is now being investigated. Further, we have other ongoing studies to determine whether the same effect occurs with different levels of neutralizing antibodies (2F5 vs b12). In CHAVI we have largely switched to examining MPER antibodies (2F5) as these are more conserved and apparently equally as effective in preventing transmission, especially when in IgG forms, and a paper is currently in preparation describing the distribution and efficacy of these antibodies in preventing vaginal SHIV transmission.
这个子项目是利用资源的许多研究子项目之一。
由NIH/NCRR资助的中心拨款提供。对子项目的主要支持
子项目的首席调查员可能是由其他来源提供的,
包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能
表示该子项目使用的中心基础设施的估计数量,
不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。
现在很清楚,肠道和其他粘膜组织在HIV感染的传播和早期发病机制中都起着重要的作用。我们目前正在确定不同同种类型的抗体是否更有利于保护阴道穹隆,并进行实验以确定是否存在优先分泌。去年我们发现,静脉注射HIV特异性抗体后,HIV特异性IgA和IgG分别优先从肠道(直肠)和阴道分泌。最初这是使用针对HIV(2F5)膜近端外部区域(MPER)的抗体进行的,但在今年收到Scripps的Dennis Burton的行政补充后,我们也使用其他非中和抗体(B12)进行了这一研究。然而,到目前为止,当使用任何IgA同型抗体时,我们还不能证明对阴道传播的不同程度的保护,事实上,免疫球蛋白水平似乎确实与保护更好地相关。这是否是同一抗体的IgA版本没有适当构象(J链等)的一个因素目前正在调查中。此外,我们还有其他正在进行的研究,以确定不同水平的中和抗体(2F5与B12)是否会产生同样的效果。在CHAVI中,我们主要转向检测MPER抗体(2F5),因为这些抗体更保守,显然在预防传播方面同样有效,特别是在免疫球蛋白形式时,目前正在准备一篇论文,描述这些抗体在防止经阴道传播SHIV方面的分布和有效性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ronald S. Veazey其他文献
The emex vivo/em pharmacology of HIV-1 antiretrovirals differs between macaques and humans
HIV-1 抗逆转录病毒药物的 emex vivo/em 药理学在猕猴和人类之间存在差异
- DOI:
10.1016/j.isci.2022.104409 - 发表时间:
2022-06-17 - 期刊:
- 影响因子:4.100
- 作者:
Carolina Herrera;Mackenzie L. Cottrell;John Prybylski;Angela D.M. Kashuba;Ronald S. Veazey;Javier García-Pérez;Natalia Olejniczak;Clare F. McCoy;Paul Ziprin;Nicola Richardson-Harman;José Alcami;Karl R. Malcolm;Robin J. Shattock - 通讯作者:
Robin J. Shattock
Differences in the kinetics of T cell accumulations in C3H/HeN (Bcg-resistant) and C57BL/6 (Bcg-susceptible) mice infected with Mycobacterium paratuberculosis.
感染副结核分枝杆菌的 C3H/HeN(Bcg 耐药)和 C57BL/6(Bcg 敏感)小鼠 T 细胞积累动力学的差异。
- DOI:
- 发表时间:
1996 - 期刊:
- 影响因子:0
- 作者:
Ronald S. Veazey;D. Horohov;J. Krahenbuhl;H. Taylor;Julian L. Oliver;Theron G. Snider - 通讯作者:
Theron G. Snider
Distinct clinical outcomes in pediatric tuberculosis: A study utilizing infant macaques exposed to aerosol emMycobacterium tuberculosis/em
- DOI:
10.1016/j.isci.2025.112899 - 发表时间:
2025-07-18 - 期刊:
- 影响因子:4.100
- 作者:
Katherine Turnbull;Eunice Vincent;Huanbin Xu;Peter J. Didier;Robert V. Blair;Lara A. Doyle-Meyers;Chad J. Roy;Smriti Mehra;Deepak Kaushal;Ronald S. Veazey;Xiaolei Wang - 通讯作者:
Xiaolei Wang
Ronald S. Veazey的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ronald S. Veazey', 18)}}的其他基金
Vaccination with invariant MHC-II-linked accessory antigens for protection from HIV infection
使用不变的 MHC-II 相关辅助抗原进行疫苗接种,以预防 HIV 感染
- 批准号:
10687874 - 财政年份:2020
- 资助金额:
$ 5.78万 - 项目类别:
Vaccination with invariant MHC-II-linked accessory antigens for protection from HIV infection
使用不变的 MHC-II 相关辅助抗原进行疫苗接种,以预防 HIV 感染
- 批准号:
10161562 - 财政年份:2020
- 资助金额:
$ 5.78万 - 项目类别:
Evaluation of the Immunogenicity and Efficacy of HIV-1 SOSIP Envelope Protein Vaccine Delivered with or without Recombinant Viral Vector Vaccines
使用或不使用重组病毒载体疫苗递送的 HIV-1 SOSIP 包膜蛋白疫苗的免疫原性和功效评估
- 批准号:
10787977 - 财政年份:2020
- 资助金额:
$ 5.78万 - 项目类别:
Vaccination with invariant MHC-II-linked accessory antigens for protection from HIV infection
使用不变的 MHC-II 相关辅助抗原进行疫苗接种,以预防 HIV 感染
- 批准号:
10463754 - 财政年份:2020
- 资助金额:
$ 5.78万 - 项目类别:
Vaccination with invariant MHC-II-linked accessory antigens for protection from HIV infection
使用不变的 MHC-II 相关辅助抗原进行疫苗接种,以预防 HIV 感染
- 批准号:
10269042 - 财政年份:2020
- 资助金额:
$ 5.78万 - 项目类别:
Evaluation of the Immunogenicity and Efficacy of HIV-1 SOSIP Envelope Protein Vaccine Delivered with or without Recombinant Viral Vector Vaccines
使用或不使用重组病毒载体疫苗递送的 HIV-1 SOSIP 包膜蛋白疫苗的免疫原性和功效评估
- 批准号:
10269960 - 财政年份:2020
- 资助金额:
$ 5.78万 - 项目类别:
Elicitation of α4β7-Competitive Antibodies in Rhesus Macaques by a Synthetic V2 Immunogen
合成 V2 免疫原在恒河猴中诱导 α4β7 竞争性抗体
- 批准号:
9559805 - 财政年份:2017
- 资助金额:
$ 5.78万 - 项目类别:
Elicitation of α4β7-Competitive Antibodies in Rhesus Macaques by a Synthetic V2 Immunogen
合成 V2 免疫原在恒河猴中诱导 α4β7 竞争性抗体
- 批准号:
10251827 - 财政年份:2017
- 资助金额:
$ 5.78万 - 项目类别:
P187 - MULTIPLY EXPOSED VAGINALLY, UNINFECTED MACAQUE MODEL
P187 - 多重暴露阴道、未感染的猕猴模型
- 批准号:
8942184 - 财政年份:2014
- 资助金额:
$ 5.78万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 5.78万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 5.78万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 5.78万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 5.78万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 5.78万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 5.78万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 5.78万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 5.78万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 5.78万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 5.78万 - 项目类别:














{{item.name}}会员




